What is HC Wainwright’s Forecast for MeiraGTx Q1 Earnings?

MeiraGTx Holdings PLC (NASDAQ:MGTX) – Equities researchers at HC Wainwright issued their Q1 2027 earnings per share estimates for shares of MeiraGTx in a report released on Monday, April 20th. HC Wainwright analyst M. Kapoor forecasts that the company will earn ($0.58) per share for the quarter. The consensus estimate for MeiraGTx’s current full-year earnings is ($1.19) per share. HC Wainwright also issued estimates for MeiraGTx’s Q2 2027 earnings at ($0.58) EPS and Q3 2027 earnings at ($0.61) EPS.

Other equities research analysts have also issued research reports about the company. Bank of America increased their price target on MeiraGTx from $14.00 to $16.00 and gave the stock a “buy” rating in a research note on Friday, March 27th. Zacks Research upgraded MeiraGTx from a “strong sell” rating to a “hold” rating in a research note on Monday, March 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of MeiraGTx in a research note on Thursday, January 22nd. Chardan Capital reiterated a “buy” rating and issued a $35.00 price target on shares of MeiraGTx in a research note on Friday, March 27th. Finally, Royal Bank Of Canada increased their price target on MeiraGTx from $16.00 to $24.00 and gave the stock an “outperform” rating in a research note on Friday. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $25.00.

MeiraGTx Stock Performance

Shares of MGTX stock opened at $10.53 on Tuesday. MeiraGTx has a 52-week low of $4.55 and a 52-week high of $11.85. The firm has a market capitalization of $857.67 million, a PE ratio of -7.42 and a beta of 1.27. The stock has a fifty day simple moving average of $8.17 and a two-hundred day simple moving average of $8.13.

MeiraGTx (NASDAQ:MGTX) last issued its quarterly earnings results on Thursday, March 26th. The company reported $0.19 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.60) by $0.79. MeiraGTx had a negative return on equity of 1,065.47% and a negative net margin of 140.31%.The business had revenue of $75.36 million during the quarter, compared to analyst estimates of $3.87 million.

Insider Transactions at MeiraGTx

In other news, CEO Alexandria Forbes sold 62,000 shares of the firm’s stock in a transaction dated Tuesday, March 24th. The stock was sold at an average price of $7.41, for a total transaction of $459,420.00. Following the completion of the transaction, the chief executive officer owned 1,449,695 shares in the company, valued at $10,742,239.95. This trade represents a 4.10% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Stuart Naylor sold 27,661 shares of the firm’s stock in a transaction dated Tuesday, April 7th. The shares were sold at an average price of $9.36, for a total value of $258,906.96. Following the transaction, the insider owned 668,505 shares of the company’s stock, valued at approximately $6,257,206.80. The trade was a 3.97% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 7.50% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. BNP Paribas Financial Markets grew its position in shares of MeiraGTx by 43.8% during the second quarter. BNP Paribas Financial Markets now owns 4,810 shares of the company’s stock valued at $31,000 after purchasing an additional 1,466 shares in the last quarter. Kennedy Capital Management LLC grew its position in shares of MeiraGTx by 2.2% during the fourth quarter. Kennedy Capital Management LLC now owns 70,738 shares of the company’s stock valued at $562,000 after purchasing an additional 1,495 shares in the last quarter. Russell Investments Group Ltd. grew its position in shares of MeiraGTx by 4.3% during the third quarter. Russell Investments Group Ltd. now owns 82,844 shares of the company’s stock valued at $682,000 after purchasing an additional 3,452 shares in the last quarter. XTX Topco Ltd grew its position in shares of MeiraGTx by 11.0% during the fourth quarter. XTX Topco Ltd now owns 38,030 shares of the company’s stock valued at $302,000 after purchasing an additional 3,766 shares in the last quarter. Finally, State of Alaska Department of Revenue purchased a new position in shares of MeiraGTx during the third quarter valued at about $33,000. Hedge funds and other institutional investors own 67.48% of the company’s stock.

MeiraGTx Company Profile

MeiraGTx Holdings plc is a clinical-stage biotechnology company dedicated to developing gene therapies for the treatment of rare diseases. Founded in 2014 as an outgrowth of research at University College London, the company focuses on leveraging adeno-associated virus (AAV) vectors to deliver functional genes to target tissues. MeiraGTx’s pipeline spans ocular, central nervous system and systemic indications, addressing conditions such as inherited retinal dystrophies and neurodegenerative disorders that currently lack effective therapies.

The company’s lead programs include AAV-based candidates designed to restore or replace defective genes underlying rare retinal diseases and to modulate cellular pathways in neurological disorders.